Advertisement

Chronic Hepatitis C

  • Stanley Martin CohenEmail author
Chapter

Abstract

Hepatitis C (HCV) is a common viral infection of the liver. It affects approximately 1.6% of the US population. Screening in the appropriate populations is essential as signs and symptoms of the disease are generally absent. In addition, there are multiple new treatments for HCV which are extremely effective and very well tolerated. In this chapter, we describe a case of HCV in an asymptomatic patient. We discuss screening strategies, evaluation of the infection, and treatment options and outcomes.

Keywords

Hepatitis C Metavir score Fibrosis Liver biopsy Cirrhosis 

Further Reading

  1. 1.
    Afdhal N, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection (ION-1 study). N Engl J Med. 2014;370:1889–98.CrossRefGoogle Scholar
  2. 2.
    American Association for the Study of Liver Disease/Infectious Disease Society of America (AASLD-IDSA). HCV guidance: recommendations for testing, managing, and treating hepatitis C. http://hcvguidelines.org. Accessed 9 Nov 2017.
  3. 3.
    CDC guidelines on HCV screening. http://www.cdc.gov/nchhstp/newsroom/HepTestingRecsPressRelease2012.html. Accessed 23 May 2012.
  4. 4.
    Feld JJ, et al. Sofosbuvir and velpatasvir for HCV genotype 1,2,4,5, and 6 infection. N Engl J Med. 2015;373:2599–607.CrossRefGoogle Scholar
  5. 5.
    Kowdley KV, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis (ION-3 study). N Engl J Med. 2014;370:1879–88.CrossRefGoogle Scholar
  6. 6.
    Rockstroh JK, et al. Efficacy and safety of grazoprevir and elbasvir in patients with hepatitis C virus and HIV co-infection (C-EDGE Co-Infection): a non-randomised, open label trial. The Lancet HIV. 2015;2:e319–27.CrossRefGoogle Scholar
  7. 7.
    Zeuzem S, et al. ENDURANCE-1: A phase 3 evaluation of the efficacy and safety of 8- versus 12-week treatment with glecaprevir/Pibrentasvir in HCV genotype 1 infected patients with or without HIV-1 co-infection and without cirrhosis. Presented as a poster at AASLD 2016, Boston MA.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Hepatology, Digestive Health InstituteUniversity Hospitals Cleveland Medical CenterClevelandUSA
  2. 2.Division of Gastroenterology and Liver DiseaseCase Western Reserve University School of MedicineClevelandUSA

Personalised recommendations